Enhancing Early Recognition and Management of FOP: Strategies for the Pediatric Clinician

Released On
June 15, 2021

Expires On
June 15, 2022

Media Type
Internet

Completion Time
90 minutes

Specialty
Pediatrics

Topic(s)
Pediatrics

Scroll to the Bottom of this Information to Begin this Course

This program is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Physician Assistants — 1.50 AAPA Category 1 CME Credit
  • Genetic Counselor: 2 CEUs

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for pediatricians, pediatric orthopedic surgeons, medical geneticists, genetic counselors, and other healthcare providers who may participate in the assessment and care of individuals with undiagnosed or diagnosed FOP.

Program Overview

Fibrodysplasia ossificans progressiva (FOP) is an inherited autosomal dominant condition that causes progressive heterotopic ossification (HO), which is the disabling conversion of connective tissue and muscle to bone. Current management strategies center around avoiding events that trigger HO, and a growing understanding of disease pathology has led to the development of targeted therapies, which are being evaluated in advanced phases of clinical trials. These investigational therapies may offer proactive treatment options that mitigate the pathology and progression of FOP. However, as an ultra-rare disease, FOP remains under- or misdiagnosed, and healthcare providers may miss distinct clinical characteristics that are highly suggestive of the disorder.

Patients often undergo unnecessary diagnostic and therapeutic interventions that may cause harm and may be precluded from accessing appropriate management. This educational activity seeks to present pediatric healthcare providers with FOP disease background and strategies to facilitate early recognition and diagnosis, as well as review the most recent clinical trial data of emerging targeted treatment strategies.

Learning Objectives

Upon completion of this activity, the learner should be able to:

  • Identify symptoms and characteristic clinical presentations of FOP to prompt timely diagnosis
  • Describe appropriate clinical, imaging, and genetic diagnostic strategies to differentially identify FOP
  • Review current supportive care principles for FOP management
  • Evaluate the mechanisms of action, clinical efficacy, and safety data on advanced investigational disease-specific therapies for FOP
  • Assess potential considerations for the use of emerging FOP-specific therapies in practice

 

Faculty

FACULTY_NAME

Robert Pignolo, MD, PhD (Chairperson)

Chair of Geriatric Medicine and Gerontology
Robert and Arlene Kogod Professor of Geriatric Medicine
Mayo Clinic College of Medicine
Rochester, MN

FACULTY_NAME

Mona Al Mukaddam, MD, MS

Assistant Professor of Clinical Medicine and Orthopaedic Surgery
Director, Penn Bone Center
Ian Cali Clinical Scholar Center for Research in FOP and Related Disorders
University of Pennsylvania
Philadelphia, PA

FACULTY_NAME

Matthew Drake, MD, PhD

Associate Professor of Medicine
Mayo Clinic College of Medicine
Rochester, MN

FACULTY_NAME

Edna Mancilla, MD

Associate Professor of Clinical Pediatrics
Perelman School of Medicine
University of Pennsylvania School of Medicine
Division of Endocrinology and Diabetes
Children’s Hospital of Philadelphia
Philadelphia, PA

 

Accreditation Statement

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Credit provided by AKH Inc., Advancing Knowledge in Healthcare.

 

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid until {Expiration Date}. PAs should only claim credit commensurate with the extent of their participation.

 

Genetic Counselor CEUs

To apply for National Society of Genetic Counselors Category 2 CEUs, please go to https://www.nsgc.org/Education-and-Events/Continuing-Education-Unit-CEU-Information/CEU-Portal-Access

 

Disclosures of Conflicts of Interest

Faculty

Robert Pignolo, MD, PhD (Chairperson)

  • Consultant: Ipsen Pharmaceuticals, Regeneron Pharmaceuticals
  • Site Principal Investigator/Contracted Research: Ipsen Pharmaceuticals, Regeneron Pharmaceuticals

 

Mona Al Mukaddam, MD, MS

  • Contracted Research: Ipsen/Clementia, Regeneron

 

Matthew Drake, MD, PhD, has no financial relationships to disclose.

Edna Mancilla, MD, has no financial relationships to disclose.

Jessica Marshall, PhD, Planner and Medical Writer, has no financial relationships to disclose.

Staff/Reviewers

Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has disclosed no financial relationships.

Trish Brignoni, AKH Director of Operations, has disclosed no financial relationships.

AKH and Catalyst Medical Education, LLC Planners and Reviewers, have disclosed no financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: tbrignoni@akhcme.com.